Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Validated Spectrophotometric Method and Thermodynamic Studies for the Determination of Cilostazol and Rivaroxaban in Pharmaceutical Preparations Using Fe-Phenanthroline System

A Validated Spectrophotometric Method and Thermodynamic Studies for the Determination of... AbstractA spectrophotometric method has been adopted for the determination of cilostazol and rivaroxaban. The method was based on the oxidation of the selected drugs by iron (III) in the presence of 1, 10-phenanthroline and formation of tris (1, 10-phenanthroline) iron (II) complex (ferroin) with λmax at 510 ± 1 nm. All experimental conditions were carefully studied and optimized. The method was obeyed beer’s law in concentration range (0.5-10 μg/ mL) for cilostazol at pH 3.5 and (30-400 μg/ mL) for rivaroxaban. The spectrophotometric measurements enabled the detection of cilostazol and rivaroxaban at 0.046 μg/ mL for cilostazol and 4.719 μg/ mL for rivaroxaban. Apparent molar absorptivity was 53.02 × 103 and 1.28 × 103 L/mol/ cm, whereas the corresponding sandell sensitivity was 0.0069 and 0.28 μg/cm-2 for cilostazol and rivaroxaban, respectively. Method validation was performed as per ICH Q2 (R1) guidelines. Furthermore, thermodynamic parameters; free energy (ΔG°), enthalpy (ΔH°) and entropy (ΔS°) of complexation were evaluated. The reliability of the procedure has been successfully ascertained by assay of pharmaceutical formulations and recovery tests by standard addition technique. The results obtained were statistically compared with those of the reference methods using student t-test and F ratio. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Analytical Chemistry Letters Taylor & Francis

A Validated Spectrophotometric Method and Thermodynamic Studies for the Determination of Cilostazol and Rivaroxaban in Pharmaceutical Preparations Using Fe-Phenanthroline System

Download PDF

A Validated Spectrophotometric Method and Thermodynamic Studies for the Determination of Cilostazol and Rivaroxaban in Pharmaceutical Preparations Using Fe-Phenanthroline System

Abstract

AbstractA spectrophotometric method has been adopted for the determination of cilostazol and rivaroxaban. The method was based on the oxidation of the selected drugs by iron (III) in the presence of 1, 10-phenanthroline and formation of tris (1, 10-phenanthroline) iron (II) complex (ferroin) with λmax at 510 ± 1 nm. All experimental conditions were carefully studied and optimized. The method was obeyed beer’s law in concentration range (0.5-10 μg/...
Loading next page...
 
/lp/taylor-francis/a-validated-spectrophotometric-method-and-thermodynamic-studies-for-ukzv0bpFgV
Publisher
Taylor & Francis
Copyright
© 2017 Har Krishan Bhalla & Sons
ISSN
2230-7532
eISSN
2229-7928
DOI
10.1080/22297928.2017.1385420
Publisher site
See Article on Publisher Site

Abstract

AbstractA spectrophotometric method has been adopted for the determination of cilostazol and rivaroxaban. The method was based on the oxidation of the selected drugs by iron (III) in the presence of 1, 10-phenanthroline and formation of tris (1, 10-phenanthroline) iron (II) complex (ferroin) with λmax at 510 ± 1 nm. All experimental conditions were carefully studied and optimized. The method was obeyed beer’s law in concentration range (0.5-10 μg/ mL) for cilostazol at pH 3.5 and (30-400 μg/ mL) for rivaroxaban. The spectrophotometric measurements enabled the detection of cilostazol and rivaroxaban at 0.046 μg/ mL for cilostazol and 4.719 μg/ mL for rivaroxaban. Apparent molar absorptivity was 53.02 × 103 and 1.28 × 103 L/mol/ cm, whereas the corresponding sandell sensitivity was 0.0069 and 0.28 μg/cm-2 for cilostazol and rivaroxaban, respectively. Method validation was performed as per ICH Q2 (R1) guidelines. Furthermore, thermodynamic parameters; free energy (ΔG°), enthalpy (ΔH°) and entropy (ΔS°) of complexation were evaluated. The reliability of the procedure has been successfully ascertained by assay of pharmaceutical formulations and recovery tests by standard addition technique. The results obtained were statistically compared with those of the reference methods using student t-test and F ratio.

Journal

Analytical Chemistry Letters – Taylor & Francis

Published: Sep 3, 2017

Keywords: Cilostazol; Rivaroxaban; Ferric-phenanthroline system; method validation; pharmaceutical formulations

References

  • Martindale 38: The Complete Drug Reference
  • Goodman & Gilman’s the pharmaco-logical basis of therapeutics
  • Basic & clinical pharmacology
  • United States Pharmacopeia-National Formulary
  • Validated stability-indicating methods for determination of cilostazol in the presence of its degradation products according to the ICH guidelines
  • Forced degradation studies of cilostazol by validated UV-spectrophotometric method
  • Spectrophotometric determination of cilostazol in tablet dosage form
  • Simultanous spectrophotometric estimation of Cilostazol and Aspirin in synthetic mixture
  • A simple spectrophotometric quantitative determination of Cilostazol in bulk and pharmaceutical dosage forms using DNPH reagent
  • HPTLC determination of cilostazol in pharmaceutical dosage forms
  • Validated high performance liquid chromatographic method for simultaneous determination of rosiglitazone, cilostazol, and 3, 4-dehydro-cilostazol in rat plasma and its application to pharmacokinetics
  • The quantitative determination of cilostazol and its four metabolites in human liver microsomal incubation mixtures by high-performance liquid chromatography
  • Hydrolytic degradation profile and RP-HPLC estimation of cilostazol in tablet dosage form
  • HPLC determination of cilostazol in tablets, and its validation
  • High performance liquid chromatographic analysis of cilostazol in human plasma with online column switching
  • Determination of Cilostazol in Human Serum by RP-HPLC [J]
  • Validation and optimization of a simple RPHPLC method for determination of Cilostazol in human serum
  • A new rp-hplc method for simultaneous estimation of telmisartan and cilostazol in synthetic mixture
  • Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography
  • Stability indicating hplc determination of cilostazol in pharmaceutical dosage forms
  • Isocratic Reversed Phase Liquid Chromatographic Method Validation for the Determination of Cilostazol in Pure and Formulations
  • A validated stability indicating high performance reverse phase liquid chromatographic method for the determination of cilostazol in bulk drug substance
  • A validated new gradient stability-indicating lc method for the simultaneous estimation of cilostazol and aspirin in bulk and tablet formulation
  • Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS
  • High Performance Liquid Chromatography, TLC Densitometry, Firstderivative and First-derivative ratio spectrophotometry for determination of Rivaroxaban and its alkaline Degradates in Bulk Powder and its Tablets
  • Area Under Curve Spectrophotometric Method for Determination of Rivaroxaban in Bulk and Tablet Formulation and Its Validation
  • Development and validation of UV spectrophotometric method for the determination of rivaroxaban
  • Second order derivative spectroscopic method for estimation of rivaroxaban in bulk and dosage form
  • New Spectrophotometric methods for the quantitative estimation of Rivaroxaban in formulations
  • High performance thin layer chromatographic method with densitometry analysis for determination of rivaroxaban from its tablet dosage form
  • A new method for development and validation for analysis of Rivaroxaban in formulation by RP-HPLC
  • A Novel RP-HPLC Method for the quantification of Rivaroxaban in Formulations
  • Enantiomeric separation of rivaroxaban by a chiral liquid chromatographic method
  • Simultaneous RP-LC method developement and validation of clopidogrel and rivaroxaban in synthetic mixture
  • Method development and acid degradation study of rivaroxaban by RP-HPLC in bulk
  • Photolytic-thermal degradation study and method development of rivaroxaban by RP-HPLC
  • Determination of rivaroxaban-a novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatography-tandem mass spectrometry
  • UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays
  • Application of chelate compounds in analytical chemistry
  • Spectrophotometric determination of etodolac in pure form and pharmaceutical formulations
  • Spectrophotometric methods for determination of ritodrine in bulk and in pharmaceutical dosage forms
  • Visible spectroscopic determination of Faropenem sodium in pharmaceutical dosage form
  • Spectrophotometric determination of pyrocathecol and pyrogallol based on their redox reaction with iron (III)/phenanthroline system
  • Spectrophotometric Method for the Determination of Oxaliplatin in Pure and Dosage Forms
  • New, simple and validated kinetics spectrophotometric method for determination of methyldopa in its pharmaceutical formulations
  • Spectrophotometric determination of meloxicam by sodium nitroprusside and 1, 10-phenanthroline reagents in bulk and its pharmaceutical formulation
  • Validation of analytical procedures: text and methodology
  • Advanced physicochemical experiments
  • Martin’s Physical Pharmacy and pharmaceutical sciences